As a result, there are numerous newly designed and synthesized chemotherapeutic agents targeting the BH-3 domains of anti-apoptotic Bcl-2 members to induce apoptosis and inhibit the function of Bcl-2/Bcl-xL proteins, which may be useful in the management and treatment of cancers (46,47). The gene discussed is BCL2L1; the disease is cancer.